Clinical Guideline and Diagnostic Algorithm of Acute Hepatitis with Unknown Origin in Children: Tehran Children’s Medical Center Protocol

Mahsa Soti Khiabani, Hosein Alimadadi, Mohammad Reza Abdolsalehi, and Maryam Sotoudeh Anvari

1Children’s Medical Center, Pediatrics Center of Excellence, Tehran, Iran
2Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran
3Pediatric Gastroenterology and Hepatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
4Department of Molecular Pathology, Tehran University of Medical Sciences, Tehran, Iran

*Corresponding author: Children’s Medical Center, Pediatrics Center of Excellence, Tehran, Iran. Email: dr.mahsasoti@outlook.com

Received 2022 December 10; Revised 2023 January 16; Accepted 2023 February 12.

Abstract

Reports of acute hepatitis with unknown origin in children have been published worldwide since April 2022. Due to the unfamiliar nature of the disease and the alarming trend of increasing reports worldwide, health workers must become aware of its diagnosis and treatment. Accordingly, the committee for developing guidelines for the Department of Pediatrics, Tehran University of Medical Sciences, prepared a clinical guideline for more efficient management of these patients. Due to the limited information about this disease, it has been tried to categorize and specify the required diagnostic and treatment measures based on the latest published data. Herein we express this algorithmic approach and diagnostic and therapeutic guidelines for acute hepatitis with unknown origin in children.

Keywords: Acute Hepatitis with Unknown Origin, Pediatrics, Diagnosis, Treatment, Algorithm

1. Background

Acute hepatitis is a term used to specify a wide variety of situations characterized by acute inflammation of the hepatic parenchyma or damage to hepatocytes resulting in increased liver function indices. Several infectious (acute viral hepatitis) and non-infectious diseases (drug-induced hepatitis, autoimmune hepatitis, cholestasis hepatitis, metastatic disease, etc.) can cause acute hepatitis in children (1). If they are ruled out through laboratory investigations, the term hepatitis of unknown origin is used.

On 5 April 2022, 10 cases of severe acute hepatitis of unknown origin in children younger than 10 years were reported from the United Kingdom and Northern Ireland (2, 3). Rapidly, the numbers increased worldwide, and several cases were reported from different countries. Until 8 July 2022, 1010 probable cases of severe acute hepatitis of unknown origin were reported from five World Health Organization (WHO) regions, which complete the WHO case definition, including 22 deaths (4-10). As of 23 April 2022, approximately 10% of cases required liver transplantation (5). Simultaneously with the global spread of this disease, three children with severe acute hepatitis of unknown origin in a children’s medical center in Iran were reported on 25 June 2022 (11).

Considering the unknown nature of this disease and the alarming trend of increasing cases worldwide (4-9), health workers must know the general approach to these patients. To achieve this goal, the Department of Pediatrics, Tehran University of Medical Sciences, has prepared a guideline for dealing with these patients.

2. Arguments

2.1. Case Definition

Confirmed: Currently, WHO and the United States Centers for Disease Control and Prevention (CDC) do not present definitive definitions.

Probable cases: Probable cases must include all the criteria: Age below 16 years, severe acute hepatitis with aspartate aminotransferase (AST) or alanine transaminase (ALT)
above 500 since 1 October 2021, and negative tests for hep-
utitis E, D, C, B, and A.

Epidemiologically linked cases: Epi-linked cases are de-
defined as patients with acute hepatitis from the beginning
of October 2021 at any age who have been in contact with
probable cases (6, 8, 12, 13).

2.2. Clinical Presentation and Disease Severity

Before the onset of the main symptoms of hepatitis, most
patients mention nausea, vomiting, abdominal pain, and
diarrhea. About a quarter of patients display fever or
respiratory symptoms. Then, the main symptoms of
hepatitis include jaundice, yellowish color of the skin and
eyes, dark-colored urine, pale stool, weakness, anorexia,
abdominal pain, and lethargy. Skin rash and the involve-
ment of joints or other organs due to the unknown course
of the disease and its causes may occur (11-16). Criteria
of disease severity include total bilirubin > 15, prothrom-
bin time (PT) > 20 or international normalized ratio (INR)
> 2 resistant to 0.2 mg/kg vitamin k administration, hy-
poglycemia, and encephalopathy (convulsions, confusion,
lethargy, change of sleep-wake rhythm, hallucinations,
delirium, lack of awareness of time and place, behavioral
and mood changes) (6, 8, 11, 14-16). It is possible that the
high level of transaminases (> 1000) also indicates the
severity of the disease. Also, PT > 20 sec, INR > 2 not treated
by vitamin K regardless of the presence of clinical hepatic
encephalopathy or PT > 15, INR > 1.5 indicates the progress
of the disease towards fulminant hepatic failure. These
cases should be notified to the children's liver transplant
centers, and if possible, the patient should be monitored
in the intensive care unit (ICU) (6, 8-16).

2.3. Diagnostic and Therapeutic Measures/Initial Intervention
(Algorithm 1, 2)

It is recommended that general practitioners and pedi-
atrians pay attention to differential diagnosis in patients
under 16 years of age, especially under 10, with nausea,
vomiting, diarrhea, and abdominal pain with or without
fever and respiratory symptoms in addition to usual treat-
ments and consider drowsiness, jaundice, dark urine, pale
stools, bruises or frequent bleeding on the body surface, se-
vere lethargy and encephalopathy symptoms in follow-up
visits. It is recommended that children under six years of
age with symptoms of hepatitis be considered for the be-
low points (Table 1) in history taking and physical exami-
nation (6, 8-15).

The necessary tests for patients suspected of acute hep-
utitis of unknown origin in children at different referral
levels are as follows (Table 2) (6-15).

2.4. Outpatient Management

In cases that do not need hospital admission, alarm
signs should be explained to the patient and his/her par-
ents. A summary of outpatient management recommenda-
tions is seen in Table 3 (6, 8-15).

2.5. Hospitalization and Inpatient Management

If the liver enzymes are high (ALT/AST > 500 L/U) and
total bilirubin > 2 - 3 (direct > 1) with at least one of the
below criteria, the patient should be hospitalized: Having
an underlying disease (immune deficiency, severe chronic
infections, chronic lung, heart, kidney, liver, nervous and
metabolic disease), PT > 15 or INR > 1.5, symptoms of en-
cephalopathy (seizures, confusion, drowsiness, changes in
the rhythm of sleep and wakefulness, hallucinations, delu-
sions, lack of awareness of time and place, behavioral and
mood changes), hypoglycemia, frequent vomiting, and
transaminase > 1000 L/U (6, 8-15).

2.6. For the Patients Who Need Hospital Admission, 11 Cate-
gories Should Be Noted in Management

2.6.1. Initial Interventions: Including the Following

A. Check vital signs and BS glucometer regularly and
perform a neurological examination.

B. Check biochemistry, complete blood count (CBC),
liver function test (LFT), ABG (arterial blood gas), ammonia
and lactate, blood, urine, and endotracheal secretion cul-
ture.

C. Etiology investigation tests according to Table 2.

D. Chest X-ray (CXR) and abdominal ultrasound.

E. Brain CT scan in case of evidence of brain herniation
or brain hemorrhage (6, 8, 11-15).

2.6.2. Transfer to the ICU

The patient with the following criteria should be trans-
ferred to the ICU: Hepatic encephalopathy, cardiovascular
instability, multiple organ dysfunction, and hypoglycemia
(blood sugar < 55 dL/mg) (6, 8, 11-15).
Table 1. Important Points in History and Physical Examination of Patients with Hepatitis

<table>
<thead>
<tr>
<th>Points</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History taking</strong></td>
<td></td>
</tr>
<tr>
<td>Recent travel in the past month</td>
<td></td>
</tr>
<tr>
<td>Contact with patients with respiratory or digestive infections or hepatitis</td>
<td></td>
</tr>
<tr>
<td>Use of chemical drugs, especially acetaminophen, antibiotics, anticonvulsants, and chemotherapy drugs, herbal and homemade ingredients</td>
<td></td>
</tr>
<tr>
<td>Consumption of wild mushrooms</td>
<td></td>
</tr>
<tr>
<td>Contact with poisons, dyes, and chemicals</td>
<td></td>
</tr>
<tr>
<td>COVID-19 vaccination history</td>
<td></td>
</tr>
<tr>
<td>Family history of liver diseases</td>
<td></td>
</tr>
<tr>
<td>Evidence of metabolic liver diseases (consanguineous parents, other children suffering from liver diseases)</td>
<td></td>
</tr>
<tr>
<td>Evidence of autoimmune diseases in the family</td>
<td></td>
</tr>
<tr>
<td>History of routine vaccination</td>
<td></td>
</tr>
<tr>
<td>Obtaining a detailed medical history regarding consumption of chemical and household drugs, new or suspicious food, and contact with poisons</td>
<td></td>
</tr>
<tr>
<td>Obtaining a detailed medical history regarding COVID-19 or other infections in the last month</td>
<td></td>
</tr>
<tr>
<td><strong>Physical examination</strong></td>
<td></td>
</tr>
<tr>
<td>Vital signs and blood pressure measurement</td>
<td></td>
</tr>
<tr>
<td>Jaundice</td>
<td></td>
</tr>
<tr>
<td>Bruising</td>
<td></td>
</tr>
<tr>
<td>Signs of encephalopathy</td>
<td></td>
</tr>
<tr>
<td>Signs of chronic liver disease including enlarged spleen or isolated liver left lobe enlargement, clubbing, and spider angioma (the presence of these findings is against the diagnosis of acute hepatitis with unknown origin)</td>
<td></td>
</tr>
<tr>
<td>Signs of cardiac and respiratory involvement</td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Necessary Tests for Patients Suspected of Acute Hepatitis of Unknown Origin in Children at Different Referral Levels

<table>
<thead>
<tr>
<th>First Level (General Practitioner and Family Physician)</th>
<th>Second Level (Children’s Outpatient Clinics and General Hospitals)</th>
<th>Third Level (Children’s Specialist and Subspecialist Hospitals)</th>
<th>Fourth Level (Children’s Subspecialist Hospitals)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC, CRP, AST, ALT, ALP, GGT, ILIRIN, BUN, Ca, Na, K, PT, INR, PTT, albumin, total protein, BG</td>
<td>HAV IgM, HEV IgM, HBS Ag, HBS Ab, HBC Ab, HCV Ab, Epstein-Barr virus VCA Ab IgM &amp; IgG, CMV IgM &amp; IgG, SARS-CoV-2 (IgM &amp; IgG), SARS-CoV-2 PCR, at the discretion of the pediatric gastroenterologist: ANA, ASMA, LKM Ab, total IgG, VBG, ceruloplasmin, ammonia, lactate</td>
<td>Blood, respiratory, or feces adenovirus PCR should be done if the second-level tests are negative (regardless of the SARS-CoV-2 test result)</td>
<td>In the case of adenovirus PCR negativity, depending on the type of symptoms (respiratory or digestive), multiplex PCR for respiratory or gastrointestinal test should be sent to the national reference laboratory</td>
</tr>
</tbody>
</table>

Abbreviations: CBC, complete blood count; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; AST, aspartate aminotransferase; ALT, alanine transaminase; ALP, alkaline phosphatase; GGT, gamma glutamyl transferase; PT, prothrombin time; INR, international normalized ratio; PTT, partial thromboplastin time; BG, blood glucose. HAV IgM, hepatitis A virus IgM antibody; HEV IgM, hepatitis E virus IgM antibody; HBS Ag, hepatitis B surface antigen; HBS Ab, hepatitis B surface antibody; HBC Ab, hepatitis B core antibody; HCV Ab, hepatitis C virus antibody; VCA Ab, viral capsid antigen antibody; CMV, cytomegalovirus, PCR, polymerase chain reaction; ANA, antinuclear antibody; ASMA, smooth muscle antibody; LKM Ab, liver/kidney microsome type 1 antibodies; VBG, venous blood gas.

2.6.3. Fluid and Electrolytes Management

Insertion of a central vein catheter is recommended with an arterial catheter, if necessary. After initial resuscitation, total intravenous fluids should be restricted to around 90% of maintenance fluids to avoid overhydration, followed by dextrose 10% with an amount of 90% maintenance with half saline and 15 meq/L potassium. Maintain blood glucose between 90 - 120 mg/dL. Hypoglycemia resistant to treatment can indicate metabolic disease or adrenal insufficiency requires hydrocortisone. Blood sodium should be maintained at 145-150 meq/L. Blood phosphorus levels should be kept above 3 (6, 8, 11-15).
Table 3. Outpatient Management of Patients with Acute Hepatitis of Unknown Origin

<table>
<thead>
<tr>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Note warning signs (sleepiness, convulsions, delirium, and other symptoms of encephalopathy, body bruising, bleeding, severe lethargy, worsening of jaundice, frequent vomiting, and food intolerance, and decreased urine volume).</td>
</tr>
<tr>
<td>Daily visits for clinical signs and symptoms</td>
</tr>
<tr>
<td>Checking PTT, INR, PT, CBC, GGT, ALP, ALT, and AST at regular intervals for deciding on hospitalization indication based on the physician’s opinion</td>
</tr>
<tr>
<td>Emphasis on nutrition with plenty of fluids, fresh fruits and vegetables, and enough calories</td>
</tr>
<tr>
<td>Emphasis on avoiding arbitrary use of chemical and household medicines</td>
</tr>
<tr>
<td>No close contact with the patient’s respiratory secretions and the content of his vomit and feces</td>
</tr>
<tr>
<td>Frequent hand washing of the patient and others with soap and water</td>
</tr>
</tbody>
</table>

Abbreviations: CBC, complete blood count; AST, aspartate aminotransferase; ALT, alanine transaminase; ALP, alkaline phosphatase; GGT, gamma glutamyl transferase; PT, prothrombin time; INR, international normalized ratio; PTT, partial thromboplastin time.

2.6.4. Infection Control

Broad-spectrum antibiotics should be administered. Tachycardia without cause, gastrointestinal or pulmonary bleeding, elevated urea and creatinine, and change in the level of consciousness can indicate an infectious process. Sepsis work-up, including blood culture, is necessary for all patients (6, 8, II-15).

2.6.5. Hepatic Encephalopathy Treatment

The head should be 30 degrees higher than the rest of the body, and the environment should be calm. Head and body protection with protective pads is recommended. Minimal endotracheal suction should be done. Protein intake should restrict to up to 1 g/kg/d. Lactulose 0.5 – 1 mL/kg (maximum 30 cc per dose) is recommended to the extent that the patient has 2 – 4 soft stools daily. Eliminating risk factors (infection, shock, hypotension, gastrointestinal bleeding, kidney failure, electrolyte disorders such as hypokalemia, and sedative drugs, especially benzodiazepines) is necessary. Tracheal intubation in case of stage 3 encephalopathy, aggressive behavior, and decreased respiratory function should be done (6, 8, II-15).

2.6.6. Brian’s Edema Treatment

Abnormality of pupillary reflex, deep tendon reflex (DTR) intensification, Babinski positivity, and hypertensive attack can indicate the onset of edema, and the following treatment should be performed for cerebral edema: Maintaining adequate perfusion, temporary hyperventilation, hypothermia, limitation of liquids administration (75% to 91% maintenance), hypertonic saline 3 – 30% administration (blood sodium should be kept at 145 - 155 meq/L), control of sepsis and convulsions (levetiracetam is preferred and sodium valproate is prohibited), mannitol administration (0.5 - 1 g/kg if serum osmolality < 320 with normal urine output).

Optic nerve sheath ultrasound can be used to check cerebral edema (6, 8, II-15).

2.6.7. Coagulopathy Treatment

Vitamin K administration 0.2 - 0.3 mg/kg, fresh frozen plasma (FFP), and platelets administration in case of active bleeding or procedure, and active 7 factor can be used in case of volume restriction and the need for immediately correcting coagulation disorders before procedures (6, 8, II-15).

2.6.8. Maintaining Renal Function

Maintain urine output above 0.5 cc/kg/h. keep systolic blood pressure above 80 - 90 mmHg according to age. Pay attention to glomerular filtration rate (GFR) in the dosage of drugs. Do not use nephrotoxic contrast agents or drugs; treatment of hypovolemia, and, if necessary, use inotrope drugs, especially norepinephrine (6, 8, II-14).

2.6.9. Maintaining Cardiovascular Function

The inotrope of choice is norepinephrine. In case of persistent hypotension, adrenal insufficiency should be considered (6, 8, II-15).

2.6.10. Liver Transplantation

In case of a progressive course of liver dysfunction (PT > 20 or INR > 2, 15 < PT or 1.5 < INR with encephalopathy,
hepatic encephalopathy, total bilirubin > 15), it is recommended to make arrangements for liver transplant (6, 8, 11-15).

2.6.11. Sedative Use

Sedatives are preferable to narcotics (14, 15).

2.7. Prevention

Preventive measures include avoiding close contact with patients’ respiratory droplets and contents of vomit, feces, urine, and blood, frequent hand washing with soap and water, and keeping children away from kindergartens and schools for at least one week after the onset of jaundice (6, 8, 11-15).

2.8. Discharge

If the patient has the following conditions, he/she can be discharged from the hospital:

1. Persistence of vital signs for at least 48 hours
2. No electrolyte disorder
3. Having oral tolerance
4. Decreasing course of liver tests, especially INR and bilirubin, in the last three days
5. Bilirubin < 15 mg/dL and INR < 1.5
6. No hypoglycemia (BS < 55 mg/dL) in the last 48 hours
7. Absence of cytopenia (6, 8, 11-15)

2.8.1. Recommendations After Discharge

1. It is recommended that the patient refer immediately in case of daytime sleepiness, convulsions, delirium, sleep-wake rhythm disturbance, frequent vomiting and severe lethargy, severe abdominal pain, bruising, and spontaneous bleeding.
2. A follow-up visit should be done in the coming days with AST, ALT, alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), CBC, PT, INR, and partial thromboplastin time (PTT) checks and comparing results with previous results, especially for bilirubin and PT/INR.
3. The patient should be taught the principles of infection control.
4. The patient should have a diet containing enough liquids, fruits, and vegetables and plenty of calories.
5. Regular outpatient visits of patients should be done weekly until the liver tests are completely normal.
6. Considering the possibility of aplastic anemia in viral hepatitis and the involvement of other organs, it is recommended to check CBC-Diff during follow-up visits (6, 8, 11-15).

3. Conclusions

Considering that this disease is spreading daily worldwide (9, 15, 16), the necessary training should be given to the health system employees to diagnose and manage these patients. A step-by-step approach helps pediatricians properly detect and treat these patients (6, 8, 14, 16). Figure 1 shows the way of step-by-step diagnostic investigations in pediatric acute hepatitis. If the diagnosis of hepatitis of unknown origin is determined based on the laboratory results, Figure 2 can be used to continue the diagnostic and therapeutic approach of the patient. The etiology of this disease is still unclear (6, 8, 11, 12, 16, 17), but studies have shown that adenovirus infection (18), autoimmune condition (19-21), and infection or vaccination of COVID-19 (20, 22, 23) may play a role in its initiation.

Acknowledgments

We sincerely thank the professors of the Guideline Writing Committee of the Children’s Department of Tehran University of Medical Sciences who helped revise this article: Mahmoud Khodabandeh, Seyed Reza Raees Karami, Vahid Ziaee, Behdad Gharib, Mahya Sadat Mohammadi, and Seyed Hossein Mirlohi.

Footnotes

Authors’ Contribution: H. A.: Study concept and design; M. A.: Drafting of the manuscript; M. S. A.: Critical revision of the manuscript for important intellectual content; M. S. K.: Drafting of the manuscript.

Conflict of Interests: This study did not have funding or research support. The authors do not have personal financial interests or professional relations with organizations and individuals.

Funding/Support: The study did not use grants or funding.
Patient with acute hepatitis plus ALT/AST>500U/L

Age < 16 years

Check of below laboratory tests:
A: HAV IgM, HEV IgM, HCV Ab, HBS Ag, HBS Ab, HBC IgM
B: EBV (VCA) (IgM, IgG)
C: SARS-COV-2 (IgM, IgG, PCR)
D: ANA, ASMA, LKM, Total IgG
E: Ammonia, lactate, ABG
F: Serum ceruloplasmin

Positive history of contact with a probable case

No history of contact with a probable case

Negative result of all tests (without considering C group test)

A or D group test Positive

Refer to pediatric gastroenterologist

B or C group test Positive

Refer to pediatric infectious disease subspecialist

Acute hepatitis with unknown origin

Epi-linked case

No probable case

No epi-linked case

Figure 1. Diagnostic approach to patients with acute hepatitis
Patient with acute hepatitis with unknown origin

Serum adenovirus PCR

Positive result

Supportive care according to pediatrics infectious disease subspecialist or pediatric gastroenterologist opinion

Negative result

Multiplex PCR (Respiratory, gastrointestinal)

Supportive Care:
- Admit patient of needed
- Note alarm signs
- Daily monitoring of liver function
- Infection control care

Figure 2. Diagnostic approach to patients with acute hepatitis with unknown origin
References


